Researchers at the Memorial Sloan Kettering Cancer Center have identified a single protein called ZFP36L2 that acts as a molecular switch linking the gut’s damage-sensing system to cellular identity shifts, according to a study published August 5 in Nature. According to physician-scientist Karuna Ganesh, senior author of the study, the protein controls how cells detect tissue damage and activate stem cell renewal programs across various tissues.
How ZFP36L2 Regulates Gut Stem Cell Repair
Under normal conditions, intestinal stem cells produce steady streams of specialized daughter cells that line the gut wall and absorb nutrients, according to research findings. As these cells mature, ZFP36L2 activity decreases to lock them into their mature identities. When injury strikes the intestine, specialized cells receive emergency signals to rewind into a stem cell state. ZFP36L2 stops this alarm by clearing messenger RNAs carrying the stress signal, allowing cells to complete their transition into stem cells. Without this protein, cells stay trapped in a stressed state and cannot repair tissue, as demonstrated in laboratory mice lacking ZFP36L2.
Did you know? Colorectal cancer cells hijack the exact same wound-healing machinery that the human gut uses to recover from inflammation and infections, allowing metastatic cells to travel through the bloodstream and seed new tumors in organs like the liver and lungs.
How Colorectal Cancer Cells Exploit the Injury-Repair Mechanism
When tumor cells break away from primary tumors and travel through the bloodstream, they enter a stressed state similar to damaged gut tissue. According to study lead author Quingwen “Karen” Jiang, cancer cells must rewind back into a stem cell state to establish new tumors in distant organs. Using organoids derived from patient colorectal cancer liver metastases, researchers found that tumors lacking ZFP36L2 largely failed to seed metastases in distant organs because the cellular reprogramming process broke down.
Treatment Resistance Risks Linked to ZFP36L2 Mutations
While disrupting ZFP36L2 stops metastasis, its loss in primary tumors creates separate treatment challenges. In roughly 5% to 10% of colorectal cancer patients, the ZFP protein is mutated or deleted entirely. According to Dr. Ganesh, cancer cells that cannot access a normal stem cell state get stuck in a stress-response state and adapt by shifting into abnormal neuroendocrine or skin squamous cell identities, which are associated with treatment resistance and worse patient outcomes.
Pro Tip: Standard tumor sequencing already detects ZFP mutations. Clinicians can monitor patients carrying these genetic alterations earlier for aggressive neuroendocrine- or squamous-like cancer characteristics.
Frequently Asked Questions
What is ZFP36L2?
ZFP36L2, or ZFP for short, is a protein identified by Memorial Sloan Kettering researchers that acts as a molecular switch connecting tissue damage sensing to cellular identity shifts.
How does ZFP36L2 affect colorectal cancer metastasis?
According to research findings, metastatic cancer cells rely on ZFP to manage stress and rewind into a stem cell state when spreading to new organs. Disrupting ZFP compromises their ability to form new tumors.
Why do ZFP mutations cause treatment resistance?
When ZFP is mutated or deleted, cancer cells cannot enter a normal stem cell state and instead shift into aggressive neuroendocrine or squamous cell identities that resist standard therapies.
To explore more breakthroughs in cancer research and molecular biology, subscribe to our newsletter or browse our latest scientific news articles.